Natera Announces Senior Leadership Appointments
18 Setembro 2023 - 10:00AM
Business Wire
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA
testing, today announced three appointments within its senior
leadership team, effective immediately.
- Solomon Moshkevich has been promoted to president of clinical
diagnostics and will lead Natera’s team of general managers across
oncology, women’s health, and organ health. In addition, Moshkevich
will have responsibility for customer service, clinical trial
operations, program management, and regulatory and quality
affairs.
- Alexey Aleshin, M.D., will succeed Moshkevich, assuming the
role of GM of oncology and early cancer detection. Dr. Aleshin will
also continue serving as chief medical officer of the company.
- John Fesko has been promoted to president & chief business
officer, with oversight of reimbursement strategy and market
access, patient operations and experience, marketing and
communications, government affairs, business and market
development, pharmaceutical services, and international commercial
operations and strategy.
“Each of these individuals has demonstrated excellent
performance and leadership in their respective areas,” said Steve
Chapman, chief executive officer. “As we embark on the next phase
of growth at Natera, these appointments of long-tenured executives
with significant experience across critical functions will allow us
to ensure consistent execution while delivering outstanding service
to our patients and customers.”
Solomon Moshkevich, president of clinical diagnostics, joined
Natera in 2011. He has played a leading role in the development,
clinical validation and commercial success of all Natera’s
cell-free DNA products including Panorama, Prospera, and Signatera.
He most recently served as general manager of oncology, a position
he assumed in 2019, overseeing a period of tremendous growth for
the company’s molecular residual disease test, Signatera, and
leading the company’s efforts to achieve Medicare coverage for
Signatera across multiple cancer types. Moshkevich began his career
as a consultant with Bain & Company in New York before joining
the private equity investment team at Parthenon Capital in Boston.
He graduated from Columbia University summa cum laude with a B.A.
in economics and mathematics, and he holds an M.B.A. from Stanford
University.
John Fesko, president & chief business officer, joined
Natera in 2014. He has held several different leadership roles of
increasing responsibility during his tenure. He was named chief
business officer in 2019, a role which has grown to include
oversight of multiple functions and teams responsible for
reimbursement strategy and market access, business and market
development, marketing and communications, government affairs,
pharmaceutical services, and international commercial operations
and strategy. Prior to Natera, Fesko worked at Roche, Novartis
Pharma AG, MPM Capital and InVivoScribe. He holds an M.B.A. from
M.I.T. and a B.S. in biochemistry and economics from the University
of Notre Dame.
Alexey Aleshin, M.D., M.B.A., general manager of oncology and
early cancer detection & chief medical officer, joined Natera
in 2017. He has served in multiple leadership capacities during his
tenure at the company, including vice president of oncology medical
affairs, general manager of early cancer detection, and chief
medical officer. Prior to Natera, Dr. Aleshin was actively involved
as an advisor and consultant at various companies focused on
advancing clinical adoption of next generation sequencing
technologies. He received his M.D. and M.B.A. from UCLA and later
completed his internal medicine residency at Stanford University
Medical Center and his hematology/oncology fellowship at Stanford
Hospital.
About Natera
Natera™ is a global leader in cell-free DNA testing, dedicated
to oncology, women’s health, and organ health. We aim to make
personalized genetic testing and diagnostics part of the standard
of care to protect health, and inform earlier, more targeted
interventions that help lead to longer, healthier lives. Natera’s
tests are validated by more than 150 peer-reviewed publications
that demonstrate high accuracy. Natera operates ISO 13485-certified
and CAP-accredited laboratories certified under the Clinical
Laboratory Improvement Amendments (CLIA) in Austin, Texas and San
Carlos, California. For more information, visit www.natera.com.
Forward-Looking Statements
All statements other than statements of historical facts
contained in this press release are forward-looking statements and
are not a representation that Natera’s plans, estimates, or
expectations will be achieved. These forward-looking statements
represent Natera’s expectations as of the date of this press
release, and Natera disclaims any obligation to update the
forward-looking statements. These forward-looking statements are
subject to known and unknown risks and uncertainties that may cause
actual results to differ materially. Additional risks and
uncertainties are discussed in greater detail in “Risk Factors” in
Natera’s recent filings on Forms 10-K and 10-Q and in other filings
Natera makes with the SEC from time to time. These documents are
available at www.natera.com/investors and www.sec.gov.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230918726010/en/
Investor Relations: Mike Brophy, CFO, Natera, Inc.,
510-826-2350, investor@natera.com Media: Lesley Bogdanow, VP of
Corporate Communications, Natera, Inc., pr@natera.com
Natera (NASDAQ:NTRA)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Natera (NASDAQ:NTRA)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024